<<Threshold will receive an upfront payment of $25 million and could receive another $55 million in additional development milestones during 2012, which includes a $20 million milestone payment based on positive results from its randomized Phase 2b trial in pancreatic cancer ("404 trial") plus another $35 million in milestones that are independent of continued development of TH-302 in pancreatic cancer>>
plus another $35M in milestones independent of TH-302.......any one have any thoughts about this on what can occur in 2012? is this just meeting enrollment and prelimin analysis milestones for the Phase 3, I can't think of any thing else...
I don't know why they are not disclosing the details of these apparent shoe-in milestones to the public. Thershhold apparently negotiated a number of low-bar milestones in that development deal in order to generate more cash and not have to do any more secondary offerings ever again. I still think this whole development deal was a bit of a ruse, which was put in place temporarily before Merck KGaA takes a majority stake in the company or simply buys the whole company after the AACR. At this point, that really looks like the only way for Merck to truly lock up this new treatment paradigm for themselves.
My thoughts, as a nurse, I am more familar with medicine than economics. In Chicago, the data presented will be encouraging and more clinics and physicians will be recruited to enroll in further clinical trials. Merck will cover the cost for those new clinical trials. This data, if positive (as I expect), will increase the chances of FDA approval and possibly at an earlier date. Merck wants this, they wouldn't risk what they are risking not to take a big stake in the company, or all of it.